{
    "2019-05-24": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Pfizer's Lyrica doesn't meet endpoint in epilepsy study",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Lyrica",
                        "epilepsy",
                        "study",
                        "endpoint"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-04-20",
                "original_text": "Pfizer Announces Top-Line Results from Phase 3 Trial of LYRICAÂ® (pregabalin) in Primary Generalized Tonic-Clonic Seizures",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "LYRICA",
                        "Phase 3",
                        "Trial",
                        "Seizures"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-10",
                "original_text": "Barrow, Hanley, Mewhinney & Strauss Trims Multiple Positions in 1st Quarter",
                "features": {
                    "keywords": [
                        "Barrow",
                        "Hanley",
                        "Mewhinney",
                        "Strauss",
                        "Trims",
                        "Positions",
                        "1st Quarter"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-06-05",
                "original_text": "3 Stocks to Win Big in the Fight Against Cancer",
                "features": {
                    "keywords": [
                        "Stocks",
                        "Win Big",
                        "Cancer"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}